Jump to content
Advertisement

Advertisement

Pubmed-Focus on Pharmacotherapy for Irritable Bowel Syndrome with Constipation


Health Reporter
 Share

Recommended Posts


Advertisement

Gastroenterol Clin North Am. 2021 Sep;50(3):639-653. doi: 10.1016/j.gtc.2021.04.004.

ABSTRACT

Irritable bowel syndrome with constipation is a common disorder that significantly impairs quality of life. There are now multiple classes of therapeutics that have been shown via rigorous clinical testing to improve the abdominal and bowel symptoms attributed to irritable bowel syndrome with constipation. These include the secretagogues (lubiprostone, linaclotide, plecanatide, tenapenor) and the prokinetic agent tegaserod. This article highlights the pivotal evidence for these agents and most recent treatment guidance from the major North American gastroenterological societies. When pharmaceuticals are used, a patient-specific approach based on efficacy, safety, tolerability, access, and affordability is recommended.

PMID:34304792 | DOI:10.1016/j.gtc.2021.04.004

View the full article



Advertisement
Link to post
Share on other sites

 Share

×
×
  • Create New...